SKYTROFA® is covered with a prior
authorization on most plans
CHECK COVERAGE
SKYTROFA® is ready to ship to your patients!
GET STARTED

Patient Preference

Mom and son with doctor.

SKYTROFA® reduces injection burden

No Injections
Up to 313 injection-free days per year
with SKYTROFA1

In a clinical trial following switch from daily somatropin to once-weekly SKYTROFA (N = 146),*

90% of surveyed caregivers preferred SKYTROFA

over daily somatropin at week 132

Reduced frequency of injections was the most important reason cited2

Treatment burden was reduced with SKYTROFA

versus daily somatropin for both children and caregivers2

CSDS-C summary score decreased by 44% from week 1 to week 26 (P = 0.0086)

CSDS-P summary score decreased by 66.7% from week 1 to week 26 (P < 0.0001)

SKYTROFA Auto-Injector is easy to use

Girl holding injector.
In the enliGHten trial,†
94% of patients (n = 115)
reported‡ that SKYTROFA could be administered using the Auto-Injector without difficulty or making a mistake3

Injection training materials are well understood

In a comprehension study (N = 135),§ following a review of injection training materials and performing a simulated injection4:

Icon of a group

≥ 95%
across all groups (HCPs, caregivers, children) were successful in their injections4

Thumbs up Icon

98%
of participants reported that they could use the device safely on their own or with caregiver supervision4

Get your patients with pediatric GHD started on SKYTROFA today

LEARN MORE
* A multicenter, phase 3, open-label, 26-week trial investigating the safety, tolerability, and efficacy of SKYTROFA administered once weekly in children with GHD. The trial included 3 treatment-naïve and 143 treatment-experienced patients previously treated with daily hGH for ≤ 130 weeks. The mean daily somatropin dose was 0.29 mg/kg/week upon entering the trial. Safety and tolerability were the primary endpoints. Patients aged 6 months to 3 years could be treatment naïve and were included only in the safety and tolerability analyses. Preference was evaluated by 2 questionnaires (one for children [PQ-C] and one for parents/caregivers [PQ-P] at weeks 6 and 13). Treatment burden was assessed using variants of the CSDS-C and CSDS-P at weeks 1 (predose), 6, 13, and 26.2
† An open-label extension study of pediatric patients with GHD who previously participated in phase 3 SKYTROFA trials. The study enrolled a total of 298 patients: 103 patients on SKYTROFA and 55 patients on a daily somatropin from the heiGHt trial, and 140 patients on SKYTROFA from the fliGHt trial. The mean age at baseline was 9.5 years for SKYTROFA-treated patients from the heiGHt trial, 9.5 years for daily somatropin-treated patients from the heiGHt trial, and 11.1 years for patients from the fliGHt trial. Long-term safety was the primary objective.3
‡ Patients at select US sites switched from administering SKYTROFA with a vial and syringe to the Auto-Injector (n = 160) once it became available. Patient-reported outcomes for the Auto-Injector based on the device usability questionnaire were available for 115 patients who completed the questionnaire after 13 weeks of Auto-Injector use.3
§ Participants had reviewed materials supplied with the Auto-Injector, including cartridges, packaging, IFU, QRG, a training video, and the Auto-Injector Help Line. They were then assessed on their performance of a simulated injection and charging of the Auto-Injector, as well as their comprehension of the IFU, followed by a debriefing discussion with the investigator. The participants included patients with pediatric GHD and proxy conditions including diabetes (n = 60), caregivers (n = 60), and HCPs (n = 15). Pediatric patient ages ranged from 6 to 12 years for females and 13 to 17 years for males.4